Dr. Sitlinger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2400 Pratt St
Ste 5000
Durham, NC 27705Phone+1 919-684-1762
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2016 - 2019- Duke University HospitalResidency, Internal Medicine, 2013 - 2016
University of Cincinnati College of MedicineClass of 2013
Certifications & Licensure
NC State Medical License 2013 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Educating Hematology-Oncology Fellows About How to Communicate with Patients About Clinical Trials: A Needs Assessment.Naomi D Parker, Martina C Murphy, Susan Eggly, Elisa S Weiss, Tithi B Amin
Journal of Medical Education and Curricular Development. 2024-08-05 - An epidemiologic study comparing cancer- and noncancer-associated venous thromboembolism in a racially diverse Southeastern United States county.Andrew M Peseski, Sargam Kapoor, Maragatha Kuchibhatla, Alys Adamski, Karon Abe
Research and Practice in Thrombosis and Haemostasis. 2024-05-01 - 1 citationsEffects of high-intensity interval training on health-related quality of life in chronic lymphocytic leukemia: A pilot study.Ashley L Artese, Andrea Sitlinger, Grace MacDonald, Michael A Deal, Erik D Hanson
Journal of Geriatric Oncology. 2023-01-01
Abstracts/Posters
- A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalid...Andrea Sitlinger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular TherapiesAndrea Sitlinger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel AgentsAndrea Sitlinger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
